Most Read Articles
6 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
6 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

3 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.

Carfilzomib once-a-week effective for relapsed, refractory multiple myeloma

23 Apr 2020

Once-weekly carfilzomib appears to be optimally beneficial for patients with relapsed and refractory multiple myeloma (RRMM) regardless of baseline disease characteristics, a recent study has shown.

Researchers conducted subgroup analyses of the phase III ARROW* study, enrolling 478 RRMM patients. Of these, 240 were given once-weekly Kd70 mg/m2 carfilzomib, while 238 were taking twice-weekly Kd27 mg/m2 doses. Outcomes included progression-free survival (PFS), overall response rate (ORR) and best overall response.

Subgroup analysis according to age found that the once-weekly dose conferred greater PFS in those <65 years of age (p=0.0024), as compared to the more frequent dosing. In both the 65–75-year and 75-year age groups, no dose was superior in terms of PFS. In comparison, ORR was significantly better with the once-weekly dose across all age groups.

A similar pattern was reported when analysis was conducted according to renal function. PFS was significantly better with the once-a-week dose across all renal function categories, except for creatinine clearance <50 mL/min, where both doses were comparable. ORR, on the other hand, was better with the less frequent dosing across all categories of renal function.

Once-weekly dosing of carfilzomib continued to be better than the twice-weekly doses when stratifying the participants for prior lines of therapy and refractory status to bortezomib, both in terms of PFS and ORR.

“Future studies evaluating the efficacy and safety of once-weekly Kd70 mg/m2 dosing relative to recommended triplet salvage regimens may further highlight the potential utility of once-weekly Kd70 mg/m2 in the RRMM treatment armamentarium,” the researcher said.

*Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
6 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

3 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.